Hong Kong delegation to showcase biotech innovations at BIO 2025
發佈日期: 2025-06-05 23:58
TVB News
The Hong Kong Science and Technology Park is set to lead a delegation of 16 life and health technology companies to the BIO 2025 Conference in Boston later this month.
This move highlights the critical importance of international science collaboration even amid geopolitical tensions and tariff disputes.
This year's delegation from Hong Kong to the BIO 2025 Conference includes 16 innovative companies.
Among them is GenEditBio, a start-up focused on developing safe and affordable in vivo genome editing therapies to treat genetic diseases.
GenEditBio's Business and Development Manager Cynthia Shum said she hoped to connect with potential investors and learn from international companies at the conference.
"U.S. BIO is a global platform. So it is a very good opportunity for us to efficiently partner with companies from all over the world."
She also explained that tariffs imposed by U.S. President Donald Trump's Administration have sparked uncertainty in the biotech industry, particularly with regards to investor confidence.
Nevertheless, representatives from other participating companies empathised the significance of attending the conference.
Philip Li, principal investigator of the Centre for Translational Stem Cell Biology, noted: "I think most of us here, including my own, we are interested in medicine and also helping patients. And I think medicine knows no boundaries. I think a patient in Hong Kong, in America, wherever you are, we face the same problems."
The participation of Hong Kong companies underscores the city's role as a bridge between East and West, leveraging its unique position as a gateway between the mainland and the international community.
The delegation hopes to form partnerships and attract business and investment opportunities to Hong Kong, further solidifying its role as a leading hub in biotechnology development.
